Swedish-Israeli joint venture to double infant formula fatty acid output by 2013

By Shane Starling

- Last updated on GMT

Related tags Infant formula Fatty acid

Swedish-Israeli joint venture to double infant formula fatty acid output by 2013
Swedish supplier AarhusKarlshamn (AAK) and Enzymotec, its Isreaeli partner in a proprietary infant formula fatty acid project, are expanding production at AAK’s Swedish base as Chinese demand booms.

Demand was growing so quickly for the trademarked InFat formulation that AAK VP Renald Mackintosh said mimicked the fatty acid ratios in typical human breast milk, the JV begun in 2006 had little option but to expand.

“We expect to double output by the start of 2013,” ​Mackintosh said, adding volumes were confidential.

He said the expansion in demand was being primarily driven by a Chinese infant formula market growing at more than 20%, growth which had proven decisive in Nestlé’s €9bn decision to buy Pfizer Nutrition this week.

The Pfizer division was the third biggest manufacturer in China’s €4.57bn infant formula market with 8%market share behind Mead Johnson with 16% and Danone with 14%. Nestlé had just 4% there.

With Chinese birth rates remaining high despite the one-child policy, the market is set to double to about €9bn by 2016.

The AAK-Enzymotec JV supplies “at least one”​ of the world’s biggest infant formula suppliers, Mackintosh said of the premium blend.

“extremely important market”

In its 2011 annual report released yesterday, AAK referenced the establishment of a sales company in China last year with, “an aim to be a global business partner with a strong local presence in order to serve our global and local customers.”

“A country-based organisation considerably strengthens our ability to deliver our speciality oils and fats to existing and new potential customers and to develop the good contacts that we have already established on the Chinese market.”

AAK sales increased 13% in 2011 to SEK16.7 million (€1.88m) from SEK14.8m (€1.67m) in 2010, with operating profit at SEK911m (€102,000).

Enzymatic process

The JV website states: InFat is based on a patented enzymatic process providing structured triglycerides with a high level of palmitic acid in the middle (sn-2) position of the triglyceride. This unique fat enables easy digestion and optimized uptake of calcium, fat recovery and energy.”

Research has linked the blend with:

  • Reduced stool hardness
  • Reduced calcium soaps formation
  • Increased calcium retention
  • Larger skeletal mineral deposition
  • Increased fat absorption and fat recovery

Related news

Show more

Related products

show more

Nutritional Solutions for Women's Health

Nutritional Solutions for Women's Health

Content provided by INNOBIO Corporation Limited | 04-Oct-2023 | White Paper

INNOBIO provides innovative solutions for women to overcome a variety of health challenges throughout the life cycle, from emotional health, PMS management,...

4 reasons children need MFGM, according to science

4 reasons children need MFGM, according to science

Content provided by Valio | 29-Sep-2023 | White Paper

In this white paper, Dr Anu Turpeinen discusses the ample scientific evidence showing why milk fat globule membrane (MFGM) is essential for children’s...

Golden Omega® Sustainability Strategy

Golden Omega® Sustainability Strategy

Content provided by LEHVOSS Nutrition | 11-Sep-2023 | Data Sheet

Commitment to sustainability at Golden Omega® is ever growing as they continue to put objectives in place to secure a better environment for the future....

Introducing a new era in infant nutrition

Introducing a new era in infant nutrition

Content provided by dsm-firmenich | 01-Sep-2023 | Research Study

Omega-3s are critical to infant health and development – but conventional omega-3 ingredients are impacting the planet.

Related suppliers

Follow us


View more